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Nails are underutilized as diagnostic tools, despite being involved in many dermatologic conditions. This paper explores new con-
cepts in the treatment of median nail dystrophy (MND), onychomycosis, and the nail pathology of hand, foot, and mouth disease
(HFMD). A Pubmed database literature search was conducted for MND treatment, onychomycosis treatment, and HFMD nail
pathology. Only papers published after January 2008 were reviewed. The results showed that 0.1% tacrolimus ointment can be an
eﬀectivetreatmentforMND.Earlystudiesonlasertherapyindicatethatitisasafeandeﬃcacious treatmentoptionforonychomy-
cosis, compared to conventional oral antifungal agents. Vicks VapoRub (The Proctor & Gamble Company, Cincinnati, OH) is
eﬀective against onychomycosis and is a reasonable option in patients who choose to forgo conventional treatments. Lastly, there
is evidence to support a correlation between HFMD and onychomadesis.
1.Introduction
Nailsareoftenunderutilizedasadiagnostictoolindermatol-
ogy, despite being involved in a wide variety of dermatologic
conditions. New ideas in pathophysiology, advances in dia-
gnostic and management techniques, and innovations in
treatment are continuously evolving in the ﬁeld of nail
disease. In this paper, we aim to shed light on some of these
fascinating developments with respect to the treatment of
median nail dystrophy (MND), onychomycosis, and the nail
pathology of hand, foot, and mouth disease (HFMD).
At a basic level, the nail unit is composed of a matrix on
a bed, surrounded by skin. The distal nail matrix is called
the lunula, which is the half-moon shape at the base of the
nail, and is responsible for the production of the ventral nail
plate. Melanocytes are also contained within the nail matrix
and are usually quiescent but may become active and impart
pigmentation to the keratinocytes in the nail plate. The nail
plate overlies the nail bed, which contains blood vessels
and nerves. Skin surrounding the nail plate composes the
perionychium, which can be further divided into proximal
and lateral nail folds and the hyponychium, the area beneath
the free edge of the nail [1].
Production of the nail plate is continuous from embry-
onic development until death. The mean growth rate of ﬁn-
gernails and toenails per month is 3mm and 1mm, respec-
tively, implying approximately 4–6 months to completely
regenerate a ﬁngernail or 8–12 months to replace a toenail.
Nail growth is linked to a number of factors, such as age,
presence of systemic and localized diseases, and medications
[1, 2].
2. Methods
Using the Pubmed database, the literature was searched in
three groups using the following terms: Group 1, “median
nail dystrophy”, “median canaliform dystrophy of Heller”,
and “treatment”; Group 2, “onychomycosis”, “treatment”,
and “laser”; and Group 3, “hand foot mouth” and “nail.” As
well, Google searches were carried out using the same terms.
Only papers published after January 2008 were reviewed
since this paper aims to provide an overview of the latest
literature. Articles published before this time period were
also used to provide background information.2 ISRN Dermatology
3. Results andDiscussion
3.1. Median Nail Dystrophy. Median nail dystrophy (MND),
also known as dystrophia unguium mediana canaliformis
or median canaliform dystrophy of Heller, is characterized
by a paramedian canal or split in the nail plate of one or
more nails [3]. Small cracks or ﬁssures that extend laterally
from the central canal or split toward the nail edge give the
appearanceofaninvertedﬁrtreeorChristmastree.Thecon-
dition is usually symmetrical and most often aﬀects the
thumbs, although other ﬁngers or toes may be involved [4].
The pathophysiology of MND is still unknown. Presum-
ably, the condition results from a temporary defect in the
matrix that interferes with nail formation [4]. Trauma has
been implicated as a causative factor [4, 5]. Habitual picking
of the nail base may be responsible for some cases [4]. Two
cases of MND have been reported following the habitual use
of personal digital assistants for 4 to 8 months [5]. The MND
resolvedinafewmonthsafterpersonaldigitalassistantusage
was discontinued [5]. It has been shown that some patients
on oral isotretinoin may develop MND, with subsequent
resolution upon discontinuation of the medication [6, 7].
Rarely, familial occurrences of MND have been reported [8].
TreatmentofMNDremainsadiﬃcultundertaking,asno
therapy has been shown to be consistently successful. Most
treatments revolve around injecting medications, such as tri-
amcinoloneacetonide,intothedystrophicnail[9].Injections
are diﬃcult to tolerate and result in numerous adverse eﬀects
for many patients. Furthermore, the eﬃcacy of such treat-
mentsisquitevariable.Themostrecentlyreportedtreatment
for MND involves topical application of 0.1% tacrolimus
ointment once daily without occlusion [4]. Kim et al. repor-
ted a 19-year-old man with MND aﬀecting both thumbnails
[4]. He was treated with a topical corticosteroid, applied
around the proximal nail fold twice a day, with no remark-
able changes after 4 weeks. He was then treated with 0.1%
tacrolimus ointment, applied on the proximal folds of both
thumbnails without occlusion every night. After 4 months,
signiﬁcant clinical improvement of both thumbnails was ob-
served. It is speculated that calcineurin inhibitors are an
eﬀective treatment due to their interference with the inﬂam-
matory component of MND [4]. Additional evidence for
the eﬀectiveness of tacrolimus in treating nail dystrophy is
seen in its successful treatment of nail dystrophy associated
with lichen planus [10]. None of the aforementioned reports
documented side eﬀects associated with the application of
tacrolimus ointment to the aﬀected nail, suggesting that it
is a safe and eﬀective therapeutic option for MND. However,
further randomized controlled trials are necessary to provide
supporting evidence for this new therapy.
3.2. Onychomycosis. Onychomycosis is a fungal infection of
the nail, presenting with nail discoloration, thickening, irri-
tation, pain, and detachment of the nail plate. A number of
organisms are responsible, including dermatophytes, non-
dermatophyte molds, and Candida. It is an exceptionally
common problem, with studies estimating its prevalence
around 14% in the general population [11]. Dermatophytes
such as Trichophyton rubrum and Trichophyton mentagro-
phytes account for 80 to 90% of all cases [12]. Nonder-
matophyte molds that can cause onychomycosis include
Acremonium species, Alternaria species, Aspergillus species,
Fusarium species, Scytalidium species, and Scopulariopsis
species [12]. Candida albicans accounts for approximately
70% of onychomycosis caused by yeasts. Predisposing factors
include hyperhidrosis, wearing occlusive shoes, participation
in sports, use of commercial swimming pools, contact with
sources of fungal infection, nail trauma, immunodeﬁciency,
diabetes mellitus, and old age.
Currenttreatmentoptionsarelessthanidealwithrespect
to eﬃcacy,sideeﬀects,andconvenience.Terbinaﬁnehaslong
been the most eﬀective oral antifungal medication for der-
matophytic infections. Studies have shown clearance rates of
76% over 12 weeks [13], but terbinaﬁne remains a non-ideal
modality due to its potential for hepatotoxicity, drug interac-
tions, and ineﬀectiveness against nondermatophytes [14].
Regarding other oral antifungal medications, Griseoful-
vin was the ﬁrst oral antifungal agent approved for use in
the US. It has signiﬁcantly more drug interactions and ad-
verse events and is less eﬀective than azoles and terbinaﬁne
[15], essentially removing it from the current dermatolo-
gist’s treatment options. Numerous studies have established
terbinaﬁne to be superior to itraconazole in the treatment of
dermatophytic onychomycosis [16]. However, itraconazole
has broader coverage for Candida and non-dermatophytic
molds. As a result, azoles are generally used as ﬁrst line in
the treatment of these less common infections. Unlike ter-
binaﬁne, azoles are fungistatic, as well as having the potential
for more adverse reactions and drug interactions, making it
diﬃcult to utilize in patients with comorbidities and poly-
pharmacy [17]. The diﬃculties with tolerability in systemic
itraconazole for onychomycosis were demonstrated in a
study by Gupta et al., where 23% of patients (n = 1063) on
200mg/day of itraconazole experienced adverse events such
as headache, rash, or gastrointestinal symptoms and 7% had
to stop treatment due to these adverse events [18].
The need for a therapeutic modality with minimal sys-
temic side eﬀects, a reasonable duration of therapy, and an
ability to deliver treatment to a conﬁned area has spurred the
recent development of several new treatments. Laser therapy
has the potential to be an ideal treatment option with respect
to its ability to deliver a high concentration of energy in a
small area. This limits systemic side eﬀects and enhances its
ability to penetrate deeper into the nail plate, eradicating
all residual fungal elements. The theoretical mechanism of
action of infrared laser is heating fungal cells to the point
of structural and functional impairment in their infectious
activity. Early evidence both in vitro and in vivo has shown
promising results for the eﬃcacy of lasers in the treatment of
onychomycosis (Table 1).
The Q-switched Nd:YAG laser with 532-nm and 1064-
nm wavelengths is capable of inhibiting the growth of T. rub-
rum in vitro. The inhibitory eﬀect is likely due to more than
simple nonspeciﬁc thermal damage [19]. Although the 532-
nm setting is well absorbed by red pigment in canthomegnin
in T. rubrum, the eﬀective inhibition of the fungus also re-
quires very short pulses of 532-nm wavelength that generateISRN Dermatology 3
Table 1: Summary of in vitro and in vivo studies demonstrating eﬃcacy of laser therapy in the treatment of onychomycosis.
Study In vitro or in vivo Laser model Outcome
Vural et al. [19] In vitro Q-switched Nd:YAG laser 532-nm and
1064-nm wavelengths Inhibition of fungal colony growth
Manevitch et al. [20] In vitro Femtosecond infrared titanium sapphire Complete clearance of T. rubrum infected nail
clippings after 4 weeks
Kozarev and Mitrovica [21] In vivo 25-millisecond pulsed Nd:YAG laser
1064nm wavelength
100% clearance in 42 nails after 3 weeks of
treatment
Hochman [22] In vivo 0.65-millisecond pulsed Nd:YAG laser
1064nm 7/8 cleared after 9 weeks of treatment
Landsman et al. [23] In vivo Dual-wavelength near-infrared diode laser
with 830-nm and 970-nm wavelengths
22/26 demonstrated improvement after 4
months of treatment
mechanical damage in the irradiated fungal colony. The
1064-nm setting is beyond the absorption spectrum of xan-
thomegnin, but its eﬀectiveness is postulated to be due to
another absorbing chromophore, such as melanin, present
in the fungal cell wall [19]. The eﬀectiveness of Q-switched
Nd:YAGlaserwith532-nmand1064-nmwavelengthshasyet
to be tested in vivo.
Manevitch et al. obtained 99 nail cuttings from patients
with onychomycosis caused by T. rubrum [20]. Nail cuttings
withpositivefungalgrowthunderwentfemtosecondinfrared
titanium sapphire laser irradiation using increasing laser
intensities with the focus scanned throughout the whole
thickness of the nail specimen. The authors found that fem-
tosecondlaserﬂuenciesof 7 × 1031 photons m−2s−1 or above
successfully inhibited the growth of the fungus in all samples
examined. However, laser intensities above 1.7 × 1032 pho-
tons m−2s−1 damaged the structure of the nail plate. These
ﬁndingssuggestthatT. rubrum onychomycosiscanbetreated
by femtosecond laser technology.
Clinically, Kozarev and Mitrovica demonstrated a 100%
clearance rate in 42 nails with onychomycosis over 12
months, with minimal side eﬀects, using a novel 25-milli-
second pulsed 1064-nm Nd:YAG laser [21]. More recently,
Hochman successfully treated 7 out of 8 onychomycosis
patients with a 0.65-millisecond pulsed Nd:YAG 1064-nm
laser over the course of two to three treatments spaced at
least 3 weeks apart, without any signiﬁcant side eﬀects [22].
Theresultsfromthisstudymayhavebeenconfoundedbythe
prophylactic daily application of antifungal cream on each
toe to prevent recolonization.
The study by Landsman et al. was the ﬁrst one to stra-
tify the patient population by severity [23]. They showed a
unique dual-wavelength near-infrared diode laser with 830-
nm and 970-nm to be eﬀective against onychomycosis of all
severities. Out of the 26 toenails treated (ten mild, seven
moderate, and nine severe), 22 (85%) displayed improve-
ment after 180 days of followup and 4 rounds of treatment
overthecourseof4months.Sixtyﬁvepercentshowedatleast
3mm,and26%showedatleast4mmofclearnailgrowth.Of
the 16 toes with moderate to severe involvement, ten (63%)
i m p r o v e d ,a ss h o w nb yc l e a rn a i lg r o w t ho fa tl e a s t3m m .
As demonstrated by these studies, laser therapy has the
potential to be an ideal treatment modality for onychomy-
cosis. Laser therapy is clean, eﬃcient, eﬀective, safe, and
tolerable. It delivers an eﬀective therapeutic dose to a limited
area,withnopotentialfordruginteractions. Exacttreatment
parameters have yet to be established, but as the number
of clinical trials increases, there is the potential to establish
consensus guidelines. The greatest impediment to the mass
implementation of laser therapy is the cost of the laser unit
itself.
Another treatment option that lacks the side eﬀects of
oral antifungal medications is Vicks VapoRub (The Proctor
& Gamble Company, Cincinnati, OH) [24]. This treatment
hasbeendiscussedinthelaymanliteraturebut,untilrecently,
has never been studied scientiﬁcally. Numerous ingredients
in Vicks VapoRub have been studied in vitro, including
thymol, menthol, camphor, and oil of Eucalyptus, and have
demonstrated eﬃcacy against dermatophytes [24].
In a recent study, Derby et al. treated 18 patients with
clinical onychomycosis that was evident on at least one great
toenailwithVicks VapoRub applied totheaﬀectednailsdaily
[24]. Patients were followed at intervals of 4, 8, 12, 36, and
48 weeks. Digital photographs were obtained during ini-
tial and follow-up visits. Primary outcome measures were
mycological cure at 48 weeks and clinical cure through sub-
jective assessment of appearance and quantiﬁable change
in the area of aﬀected nail by digital photography analysis.
Fifteen (83%) patients showed a positive treatment eﬀect; 5
(27.8%) had a mycological cure and clinical cure at 48 weeks;
10 (55.6%) had partial clearance; 3 (16.7%) showed no
change. Despite not everyone demonstrating improvement,
all18participantswere“satisﬁed”or“verysatisﬁed”withthe
nail appearance, based on a 5-point Likert scale survey. The
limitations of the study include its small sample size, lack
of control group, and variability in the infectious agent.
Although there is insuﬃcient evidence to recommend it as
a ﬁrst line treatment, this study demonstrates that there is
some eﬃcacy for Vicks VapoRub. Given its very localized ef-
fects and safety proﬁle, it is not unreasonable to recommend
this treatment in patients with contraindications to, lack of
access to, or who refuse conventional options.
3.3. Nail Pathology in Hand, Foot, and Mouth Disease.
HFMD is usually caused by coxsackievirus A 16. Less com-
monly,itiscausedbycoxsackievirusA4,A5,A6,A7,A9,A10,
A24, B2 to B5, enterovirus 71, and echoviruses [25]. All are4 ISRN Dermatology
RNA viruses and they spread by fecal-oral and respiratory
routes. Spread to other family members commonly occurs.
HFMD is characterized by vesicular stomatitis and cuta-
neous lesions on the palms and soles. The disease has an
incubation period of 3 to 6 days [26]. There is usually a
mild prodrome consisting of low-grade fever, anorexia, sore
mouth,andmalaise.Childrenyoungerthan10yearsaremost
commonlyaﬀected.Orallesionsoccurchieﬂyontheanterior
buccal mucosa and tongue, where the vesicular surfaces are
eroded rapidly, leaving ulcers with erythematous borders
[26]. The lesions on the palms and soles are papules or
vesicles on a surrounding zone of erythema. Less commonly,
the dorsal or lateral surfaces of the hands and feet may also
been aﬀected. Involvement of the buttocks is common, but
typicallythereisalackofvesiculation[26].Theeruptionsare
nonpruritic and usually resolve without crusting [25]. The
association between HFMD and onychomadesis was ﬁrst
proposedbyClementzandManciniin2000andBernieretal.
in 2001 [27, 28]. Onychomadesis is the spontaneous sepa-
ration of the nail plate from the matrix starting at the pro-
ximaledge andis theresultofthetemporary cessationofnail
formation [4]. Recently, authors in Spain and Finland have
brought forth evidence to solidify the association between
these conditions [29–33].
A study of an outbreak of HFMD in daycare centers and
schools during the fall of 2008 in Finland led to one charac-
teristic feature being found amongst the infected population:
shedding of the nail plate approximately 1-2 months after
the onset of classic HFMD symptoms [29]. Redondo et al.
documented a similar onychomadesis observation during an
HFMD outbreak in Valencia, Spain in the winter of 2008
[30]. Fifteen children and one adult presented with nail
changes consistent with onychomadesis, a mean of 6 weeks
after the clinical diagnosis of HFMD. The nail changes
were temporary with spontaneous normal regrowth in 1–4
months.
Three other studies of HFMD epidemics revealed similar
associations between onychomadesis and HFMD [31–33].
One study found that out of 221 patients with onychomade-
sis presenting during an HFMD outbreak, 134 (61%) had
HFMD [33]. The median duration between the clinical diag-
nosis of HFMD and observation of onychomadesis was 39
days. Of note, this study represents the ﬁrst identiﬁcation of
the etiologic agents responsible for onychomadesis seen with
HFMD [33]. Bernier et al. initially proposed that multiple
enterovirus strains were capable of causing the onychomade-
sis, and the ﬁndings of this study support that hypothesis
[28].
The potential causal relationship between enterovirus
causing HFMD and onychomadesis has never been proven
and is only a well-deﬁned temporal relationship. One poten-
tial explanation for the relationship between the two, aside
from enterovirus causing onychomadesis, is intensive hygie-
nicmeasuresduringHFMDoutbreaksleadingtomaceration
and a local environment favoring Candida infection and
allergic contact dermatitis, both of which can cause ony-
chomadesis [34]. Haneke suggests that proximal nail bed
inﬂammation in HFMD may cause the nail dystrophy, which
is a more likely explanation of the association [34]. The
author also notes that viral determination from stool and
pharynx samples takes 1–3 weeks following the diagnosis of
onychomadesisandthus,betweensevenandnineweeksafter
the HFMD infection [34]. To further compound this issue,
HFMD is a self-resolving condition that has a natural time
course of approximately one week. This severely limits the
ability to implicate the virus causing HFMD as the de facto
causative agent of onychomadesis following HFMD. If ano-
ther HFMD outbreak were to occur, it may be possible to
take weekly swabs from under the nails of HFMD- aﬄic-
ted patients and send them for viral analyses. This would
allow for the establishment of the nail microbial milieu and
comparison between those patients who develop onychoma-
desis and those who do not, to determine if the virus causing
HFMD is present in the dystrophic nail.
4. Conclusion
Rapid advances have been made in the ﬁeld of nail der-
matology as demonstrated through the examples of MND,
onychomycosis, and HFMD. It has been shown that MND
can be eﬀectively treated by daily applications of 0.1% tacro-
limus ointment [4]. Current treatment options, including
corticosteroid injections, are highly uncomfortable for the
patient and have not been shown to be consistently eﬀective
[9]. Lasers are a safe and eﬃcacious treatment option for
onychomycosis and have the potential to become part of the
ﬁrst line therapies with more evidence [19–23]. Compared
to oral antifungal agents, laser treatments have minimal sys-
temic side eﬀe c t s ,a r em o r ee ﬀective, and have no risk for
drug interactions. Vicks VapoRub has also been shown to
be eﬀective in the treatment of onychomycosis without side
eﬀects and is a reasonable option in patients who choose
to forgo conventional treatments [24]. Lastly, there is new
evidence to support a correlation between HFMD and ony-
chomadesis [29–33]. This is useful when advising patients
what to expect following an episode of HFMD or if ony-
chomadesis is the initial presentation, to seek a history of
HFMD as a potential etiology. Given the vast number of skin
diseaseswithnailmanifestationsandnumberofprimarynail
conditions, it is prudent to have a ﬁrm understanding of how
tomanageandtreatnailpathologyusingtherapiessupported
by the latest scientiﬁc evidence.
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